Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER-Lung: Emapalumab for Acute Lung Allograft Dysfunction
NCT07538336Phase 2Not yet recruiting
- Sponsor
- University of California, San Francisco
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in acute lung allograft dysfunction (ALAD), sponsored by University of California, San Francisco. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
emapalumab
03
Conditions
acute lung allograft dysfunction (ALAD)
Beyond the preview
Go deeper on NCT07538336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538336.